SequelSEC

MACROGENICS INC MGNX

Pharmaceutical Preparations · CIK 0001125345 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$32.83M
Fiscal year ended 2026-06-30
Operating income
-$13.85M
Fiscal year ended 2026-06-30
Free cash flow
-$41.55M
Fiscal year ended 2026-06-30

MACROGENICS INC (MGNX) reported revenue of $32.83M and net income of $19.52M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from MACROGENICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MACROGENICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$32.83M$20.78M$41.23M$72.84M$6.87M$13.19M$19.35M$110.71M$10.80M$9.10M
Cost of revenueUnavailableUnavailable$0$0$0$0$233.00K$168.00K$176.00K$270.00K
Gross profitUnavailableUnavailable$41.23M$72.84MUnavailableUnavailable$19.12M$110.54M$10.62M$8.83M
Operating income-$13.85M-$33.44M-$12.10M$18.64M-$43.22M-$42.62M-$52.84M$54.19M-$58.18M-$53.75M
Net income$19.52M-$36.77M-$14.16M$16.82M-$36.25M-$41.04M-$15.42M$56.31M-$55.66M-$52.19M
Research & development$38.78M$34.97M$33.97M$32.71M$40.79M$39.70M$38.89M$40.54M$51.73M$46.03M
Weighted-average diluted sharesshares 63.59Mshares 63.45MUnavailableshares 63.28Mshares 63.14Mshares 62.97MUnavailableshares 62.87Mshares 62.66Mshares 62.29M
Pretax income-$69.64MUnavailable-$14.93M$16.82M-$42.61MUnavailable-$14.48M$56.31M-$55.66MUnavailable
Income tax expense$0Unavailable-$777.00K$0$105.00KUnavailable$944.00K$0$0Unavailable
Diluted EPS$0.31$-0.58Unavailable$0.27$-0.57$-0.65Unavailable$0.90$-0.89$-0.84
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$7.90M$9.71M$9.24M$9.90M$9.30M$10.72M$27.81M$14.10M$14.42M$14.71M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

MACROGENICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$113.91M$66.52M$57.22M$80.13M$130.69M$145.57M$182.84M$179.62M$83.93M$80.36M
Total assets$345.41M$217.87M$256.85M$270.76M$245.42M$224.56M$261.66M$264.49M$201.14M$248.28M
Current assets$321.69M$182.52M$219.94M$232.09M$204.94M$182.09M$217.49M$222.20M$156.95M$202.58M
Total liabilities$302.54M$196.68M$201.26M$203.76M$198.80M$145.45M$145.60M$144.43M$143.32M$142.13M
Current liabilities$108.82M$95.94M$43.12M$44.47M$39.00M$55.44M$55.53M$59.31M$57.91M$55.76M
Total equity incl. NCI$42.87M$21.20M$55.59M$67.00M$46.62M$79.12M$116.06M$120.07M$57.82M$106.15M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailable$9.50M$7.91M$8.75M$9.28M$9.43M$0$3.24M$1.12M$1.25M
Accounts receivable$24.60M$10.42M$427.00K$69.23M$12.53M$10.54M$4.31M$8.75M$6.19M$7.22M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.44M$4.29M$3.26M$5.94M$4.66M$6.62M$5.01M$6.61M$5.24M$10.69M

Cash flow

MACROGENICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$40.75M-$35.81M$43.02M-$30.19M-$46.98M-$46.89M-$38.41M$60.16M-$44.48M-$45.64M
Capital expenditures$806.00K$344.00K$244.00K$426.00K$715.00K$529.00K$620.00K$592.00K$1.04M$1.46M
Investing cash flow$27.96M$45.32M-$65.99M-$20.37M-$37.64M$9.90M$41.47M$35.60M$47.44M$24.79M
Financing cash flow$60.17M-$207.00K$57.00K$0$69.74M-$282.00K$155.00K-$68.00K$625.00K$248.00K
Net change in cash$47.39M$9.30M-$22.91M-$50.56M-$14.88M-$37.27M$3.22M$95.69M$3.58M-$20.60M
Stock-based compensation$1.97M$2.65M$2.66M$3.55M$3.69M$4.39M$11.26M$5.97M$6.65M$5.55M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$708.00K$1.69M$1.70M$1.79M$1.91M$1.77M$2.05M$1.84M$1.81M$1.84M

Derived

MACROGENICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$41.55M-$36.16M$42.78M-$30.61M-$47.70M-$47.42M-$39.03M$59.57M-$45.52M-$47.10M
Gross marginUnavailableUnavailable100.0%100.0%UnavailableUnavailable98.8%99.8%98.4%97.0%
Operating margin-42.2%-161.0%-29.3%25.6%-629.3%-323.1%-273.0%48.9%-538.9%-590.4%
FCF margin-126.6%-174.0%103.8%-42.0%-694.4%-359.5%-201.7%53.8%-421.6%-517.4%
SBC / revenue6.0%12.7%6.5%4.9%53.7%33.2%58.2%5.4%61.6%61.0%
Current ratio2.96x1.90x5.10x5.22x5.26x3.28x3.92x3.75x2.71x3.63x
Revenue YoY growth378.0%57.5%113.0%-34.2%-36.4%44.9%80.5%964.8%-17.8%-62.8%
Net margin59.4%Unavailable-34.3%23.1%-527.7%Unavailable-79.7%50.9%UnavailableUnavailable
R&D / revenue118.1%168.3%82.4%44.9%593.8%300.9%201.0%36.6%479.1%505.6%
CapEx / revenue2.5%1.7%0.6%0.6%10.4%4.0%3.2%0.5%9.6%16.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable0.0%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MGNX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.